Surufatinib (Sulanda) 18 (Fig. 6) is an oral multi-kinase inhibitor with dual function against angiogenesis (VEGFR-1, -2, -3 and FGFR) and tumor immune evasion (CSF-1R: colony stimulating factor-1 receptor). This evidence concerns the gene CSF1R and neoplasm.